BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 556 filers reported holding BIO-TECHNE CORP in Q3 2021. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $667,086 | -15.8% | 9,800 | +1.0% | 0.02% | -16.7% |
| Q2 2023 | $791,811 | +4.6% | 9,700 | -4.9% | 0.02% | -5.3% |
| Q1 2023 | $756,738 | +90310.8% | 10,200 | +1.0% | 0.02% | -17.4% |
| Q4 2022 | $837 | -99.9% | 10,100 | +304.0% | 0.02% | +9.5% |
| Q3 2022 | $710,000 | -18.9% | 2,500 | 0.0% | 0.02% | -8.7% |
| Q2 2022 | $876,000 | -17.5% | 2,500 | 0.0% | 0.02% | -8.0% |
| Q1 2022 | $1,062,000 | -17.9% | 2,500 | 0.0% | 0.02% | -10.7% |
| Q4 2021 | $1,293,000 | +11.2% | 2,500 | +4.2% | 0.03% | 0.0% |
| Q3 2021 | $1,163,000 | -74.4% | 2,400 | -76.2% | 0.03% | -74.5% |
| Q2 2021 | $4,548,000 | +17.9% | 10,100 | 0.0% | 0.11% | +8.9% |
| Q1 2021 | $3,857,000 | +25.2% | 10,100 | +4.1% | 0.10% | +13.5% |
| Q4 2020 | $3,080,000 | +29.5% | 9,700 | +1.0% | 0.09% | -19.1% |
| Q3 2020 | $2,378,000 | -5.2% | 9,600 | +1.1% | 0.11% | -26.7% |
| Q2 2020 | $2,509,000 | +43.8% | 9,500 | +3.3% | 0.15% | +18.1% |
| Q1 2020 | $1,745,000 | -13.6% | 9,200 | 0.0% | 0.13% | +27.0% |
| Q4 2019 | $2,019,000 | +12.2% | 9,200 | 0.0% | 0.10% | +5.3% |
| Q3 2019 | $1,800,000 | -11.3% | 9,200 | -5.2% | 0.10% | -6.9% |
| Q2 2019 | $2,030,000 | +1.2% | 9,700 | -4.0% | 0.10% | +2.0% |
| Q1 2019 | $2,005,000 | +38.6% | 10,100 | +1.0% | 0.10% | +22.0% |
| Q4 2018 | $1,447,000 | -31.2% | 10,000 | -2.9% | 0.08% | -8.9% |
| Q3 2018 | $2,102,000 | +40.7% | 10,300 | +2.0% | 0.09% | +34.3% |
| Q2 2018 | $1,494,000 | +0.9% | 10,100 | +3.1% | 0.07% | -1.5% |
| Q1 2018 | $1,480,000 | +20.2% | 9,800 | +3.2% | 0.07% | +21.4% |
| Q4 2017 | $1,231,000 | +1.8% | 9,500 | -5.0% | 0.06% | -1.8% |
| Q3 2017 | $1,209,000 | +6.1% | 10,000 | +3.1% | 0.06% | +1.8% |
| Q2 2017 | $1,140,000 | +19.2% | 9,700 | +3.2% | 0.06% | +16.7% |
| Q1 2017 | $956,000 | +1.1% | 9,400 | +2.2% | 0.05% | -2.0% |
| Q4 2016 | $946,000 | -10.9% | 9,200 | -5.2% | 0.05% | -12.5% |
| Q3 2016 | $1,062,000 | -4.8% | 9,700 | -2.0% | 0.06% | -5.1% |
| Q2 2016 | $1,116,000 | +14.6% | 9,900 | -3.9% | 0.06% | +15.7% |
| Q1 2016 | $974,000 | +5.1% | 10,300 | 0.0% | 0.05% | +8.5% |
| Q4 2015 | $927,000 | +0.2% | 10,300 | +3.0% | 0.05% | -2.1% |
| Q3 2015 | $925,000 | -4.1% | 10,000 | +2.0% | 0.05% | +4.3% |
| Q2 2015 | $965,000 | +1.3% | 9,800 | +3.2% | 0.05% | +2.2% |
| Q1 2015 | $953,000 | +2.1% | 9,500 | -5.9% | 0.04% | +4.7% |
| Q4 2014 | $933,000 | – | 10,100 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |